MindWalk Holdings (HYFT) Net Income towards Common Stockholders (2020 - 2026)
MindWalk Holdings (HYFT) reported Net Income towards Common Stockholders of $310.57 for Q1 2026, down 99.9% year-over-year from $303608.0 in Q1 2025, and down 56.66% quarter-over-quarter from $716.55 in Q4 2025.
MindWalk Holdings (HYFT) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has 7 years of Net Income towards Common Stockholders data on file, last reported at $310.57 in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at $310.57, down 99.9% year-over-year; the trailing twelve-month figure through Jan 2026 was -$227.0 million (down 262.0% YoY), and the FY2025 annual result was -$21.7 million, down 12.69% from the prior year.
- Net Income towards Common Stockholders declined to $310.57 in Q1 2026 per HYFT's latest filing, from $716.55 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $155.6 million in Q3 2024 and troughed at -$227.0 million in Q2 2025.
- A 5-year average of -$6.2 million and a median of -$3478.7 in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders plunged 37847040.45% in 2023, then jumped 5128008.58% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$5.89 in 2022, then tumbled by 37847040.45% to -$2.2 million in 2023, then soared by 132.65% to $727895.0 in 2024, then slumped by 99.9% to $716.55 in 2025, then slumped by 56.66% to $310.57 in 2026.
- Business Quant data shows HYFT's Net Income towards Common Stockholders at $310.57 in Q1 2026, $716.55 in Q4 2025, and $821.67 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | MindWalk Holdings | 166.20 Mn | 156.06 Mn | 1.78 | 310.57 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 310.57 |
| Oct 31, 2025 | 716.55 |
| Jul 31, 2025 | 821.67 |
| Apr 30, 2025 | -226.99 Mn |
| Jan 31, 2025 | 303,607.97 |
| Oct 31, 2024 | 727,894.97 |
| Jul 31, 2024 | 155.56 Mn |
| Apr 30, 2024 | -16.47 Mn |
| Jan 31, 2024 | -2.45 Mn |
| Oct 31, 2023 | -2.23 Mn |
| Jul 31, 2023 | -3,033.53 |
| Apr 30, 2023 | -6.39 Mn |
| Jan 31, 2023 | -3.40 Mn |
| Oct 31, 2022 | -5.89 |
| Jul 31, 2022 | -7,892.68 |
| Apr 30, 2022 | -3.38 Mn |
| Jan 31, 2022 | -3,478.73 |
| Oct 31, 2021 | -3,837.99 |
| Jul 31, 2021 | -67,125.93 |
| Apr 30, 2021 | -2.46 Mn |